TSS
MCID: TXC005
MIFTS: 61

Toxic Shock Syndrome (TSS)

Categories: Infectious diseases

Aliases & Classifications for Toxic Shock Syndrome

MalaCards integrated aliases for Toxic Shock Syndrome:

Name: Toxic Shock Syndrome 12 74 54 15 71 32
Septic Shock 17 32
Staphylococcal Toxic Shock Syndrome 71
Shock, Septic 43
Toxic Shock 12
Tss 12

Classifications:



External Ids:

Disease Ontology 12 DOID:14115
ICD9CM 34 040.82
MeSH 43 D012772
NCIt 49 C35498
SNOMED-CT 67 18504008
ICD10 32 A48.3 R57.2
UMLS 71 C0600327 C3714602

Summaries for Toxic Shock Syndrome

Disease Ontology : 12 A commensal bacterial infectious disease that results in infection, has material basis in Streptococcus pyogenes or has material basis in Staphylococcus aureus , which produce toxins that are absorbed systemically and produce the systemic manifestations. The infection has symptom fever, has symptom rash, has symptom hypotension, has symptom multiorgan failure, has symptom desquamation, has symptom vomiting, has symptom diarrhea, has symptom headache, and has symptom nonfocal neurologic abnormalities.

MalaCards based summary : Toxic Shock Syndrome, also known as septic shock, is related to staphylococcal toxic shock syndrome and streptococcal toxic-shock syndrome, and has symptoms including hypotension, vomiting and fever. An important gene associated with Toxic Shock Syndrome is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Simvastatin and Methylene blue have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and lung, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Toxic shock syndrome (TSS) is a condition caused by bacterial toxins. Symptoms may include fever, rash,... more...

Related Diseases for Toxic Shock Syndrome

Diseases related to Toxic Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1176)
# Related Disease Score Top Affiliating Genes
1 staphylococcal toxic shock syndrome 35.1 TNF IL1B IFNG HMGB1 CIITA
2 streptococcal toxic-shock syndrome 34.7 TNF MYOM2 LTA IL6 IL2 CXCL8
3 fasciitis 31.2 TNF MYOM2 IL6 IL2 IL1RN IFNG
4 neisseria meningitidis infection 31.2 TLR4 TLR2 IL1RN
5 exanthem 31.2 TNF IL6 IL2 IL1RN IL10 CXCL8
6 haemophilus influenzae 31.1 TNF TLR2 CXCL8
7 scarlet fever 31.1 TNF MYOM2 EDNRA CRP
8 cellulitis 31.0 TNF IL6 IL10 CRP
9 myositis 31.0 TNF IL6 IL2 IL1B IFNG CXCL8
10 lymphopenia 31.0 IL6 IL4 IL2 IL10 IFNG
11 endomyocardial fibrosis 31.0 TNF IL4 IL10
12 necrotizing fasciitis 31.0 MYOM2 LTA IL6 IL2 IL1RN CXCL8
13 influenza 30.9 TNF IL6 IL1B IFNG CXCL8
14 acute pyelonephritis 30.9 IL6 IL10 CXCL8 CRP
15 chikungunya 30.9 TNF IL6 IL1B
16 adult respiratory distress syndrome 30.9 TNF LBP IL6 IL1B IL10 CXCL8
17 impetigo 30.9 MYOM2 IL6 EDNRA
18 vaginal discharge 30.9 IL6 CXCL8 CRP
19 disseminated intravascular coagulation 30.9 TNF SERPINC1 IL6 IL10 HMGB1 CRP
20 diarrhea 30.8 TNF TLR4 IL6 IL2 IL1B IL10
21 cytomegalovirus infection 30.8 TNF IL6 IL1B CXCL8
22 pharyngitis 30.8 TNF MYOM2 IL6 IL1RN IL1B CXCL8
23 miliary tuberculosis 30.8 TNF IFNG CRP
24 kawasaki disease 30.8 TNF IL6 IL4 IL1B IL10 CRP
25 newborn respiratory distress syndrome 30.7 IL6 IL1B HMGB1 CXCL8
26 hypereosinophilic syndrome 30.7 IL4 IL2 IL10 IFNG CXCL8
27 varicose veins 30.7 TNF SERPINC1 IL6 CXCL8
28 diphtheria 30.7 TNF IL4 IL2 IFNG
29 polyneuropathy 30.7 TNF IL6 IL1B CRP
30 rheumatic fever-related antigen 30.7 TLR2 MYOM2
31 chickenpox 30.7 TNF IL6 IL4 IL2 IL10 IFNG
32 intracranial hypertension 30.7 TNF SERPINC1 IL1B
33 pustulosis of palm and sole 30.7 TNF IL1RN CXCL8
34 purpura 30.6 TNF SERPINC1 IL6 IL4 IL10 CRP
35 spotted fever 30.6 TNF IL10 IFNG
36 dengue shock syndrome 30.6 TNF IL6 IL1RN IL1B
37 osteonecrosis 30.6 TNF SERPINC1 IL10
38 mastitis 30.5 TLR2 LBP IL6 IL1RN EDNRA CXCL8
39 pyuria 30.5 IL6 CXCL8 CRP
40 meningoencephalitis 30.5 TNF IL6 IL10 CRP
41 endometritis 30.5 TNF TLR4 TLR2 IL6 IL1B CXCL8
42 bullous impetigo 30.5 IL6 EDNRA
43 human immunodeficiency virus type 1 30.5 TNF LTA IL6 IL2 IL10 IFNG
44 acute cystitis 30.5 TNF TLR4 TLR2 IL6 IL10 CXCL8
45 encephalitis 30.5 TNF IL6 IL1B IL10
46 diverticulitis 30.5 TNF IL6 CRP
47 systemic onset juvenile idiopathic arthritis 30.5 TNF IL1RN IL1B
48 immune deficiency disease 30.5 TNF IL6 IL4 IL2 IL10 IFNG
49 mycobacterium chelonae 30.5 TLR2 CXCL8
50 trichomoniasis 30.5 TNF IL6 IL2 CXCL8

Graphical network of the top 20 diseases related to Toxic Shock Syndrome:



Diseases related to Toxic Shock Syndrome

Symptoms & Phenotypes for Toxic Shock Syndrome

Symptoms:

12
  • hypotension
  • vomiting
  • fever
  • headache
  • diarrhea
  • rash
  • multiorgan failure
  • desquamation
  • nonfocal neurologic abnormalities

UMLS symptoms related to Toxic Shock Syndrome:


shock without mention of trauma

MGI Mouse Phenotypes related to Toxic Shock Syndrome:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 CIITA EDNRA IFNG IL10 IL1B IL1RN
2 homeostasis/metabolism MP:0005376 10.36 CIITA CRP EDNRA IFNG IL10 IL1B
3 immune system MP:0005387 10.33 CIITA CRP EDNRA IFNG IL10 IL1B
4 cardiovascular system MP:0005385 10.32 CRP EDNRA IFNG IL10 IL1B IL1RN
5 endocrine/exocrine gland MP:0005379 10.18 CIITA EDNRA IFNG IL10 IL2 IL4
6 digestive/alimentary MP:0005381 10.15 EDNRA IFNG IL10 IL2 IL4 IL6
7 integument MP:0010771 10.07 EDNRA IFNG IL10 IL1B IL1RN IL4
8 liver/biliary system MP:0005370 10.06 IFNG IL10 IL2 IL4 IL6 LBP
9 neoplasm MP:0002006 9.91 IFNG IL10 IL1B IL2 IL6 TLR2
10 respiratory system MP:0005388 9.85 EDNRA IFNG IL10 IL2 IL4 IL6
11 skeleton MP:0005390 9.73 CIITA EDNRA IFNG IL10 IL1B IL1RN
12 vision/eye MP:0005391 9.32 EDNRA IFNG IL10 IL2 IL4 IL6

Drugs & Therapeutics for Toxic Shock Syndrome

Drugs for Toxic Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 438)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4 79902-63-9 54454
2
Methylene blue Approved, Investigational Phase 4 61-73-4
3
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
4
Enoximone Approved, Investigational Phase 4 77671-31-9 53708
5
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
8
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
9
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
10
Zinc Approved, Investigational Phase 4 7440-66-6 32051
11
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
12
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
13
Adenosine Approved, Investigational Phase 4 58-61-7 60961
14
Vancomycin Approved Phase 4 1404-90-6 441141 14969
15
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
16
Dipyridamole Approved Phase 4 58-32-2 3108
17
Copper Approved, Investigational Phase 4 7440-50-8 27099
18
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
19
Colistin Approved Phase 4 1066-17-7, 1264-72-8 5311054
20
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
21
Pantoprazole Approved Phase 4 102625-70-7 4679
22
Metronidazole Approved Phase 4 443-48-1 4173
23
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
24
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
25
Lorazepam Approved Phase 4 846-49-1 3958
26
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
27
Etomidate Approved Phase 4 33125-97-2 36339 667484
28
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
29
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
30
Dobutamine Approved Phase 4 34368-04-2 36811
31
Propafenone Approved Phase 4 54063-53-5 4932
32
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
33
Succinylcholine Approved Phase 4 306-40-1 5314
34
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
35
Milrinone Approved Phase 4 78415-72-2 4197
36
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
37
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
38
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
39
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
40
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
41
Enoxaparin Approved Phase 4 9005-49-6 772
42
Digoxin Approved Phase 4 20830-75-5 30322 2724385
43
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
44
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
45
Ephedrine Approved Phase 4 299-42-3 9294
46
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
47
Phenylephrine Approved Phase 4 59-42-7 6041
48
Pseudoephedrine Approved Phase 4 90-82-4 7028
49
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
50
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754

Interventional clinical trials:

(show top 50) (show all 957)
# Name Status NCT ID Phase Drugs
1 The Effect of Early Goal Directed Sedation on Microcirculation in Septic Shock Patients With Mechanical Ventilation Unknown status NCT02612363 Phase 4 Dexmedetomidine for sedation
2 The Effect of Dexmedetomidine on Microcirculation in Septic Shock- A Double-blinded Study Unknown status NCT02612181 Phase 4 Dexmedetomidine for dexmedetomidine group
3 Simvastatin in Patients With Septic Shock Unknown status NCT00450840 Phase 4 Simvastatin
4 COMPACT (COMbining Plasma-filtration and Adsorption Clinical Trial): Efficacy and Safety of High Doses CPFA (Coupled Plasma Filtration Adsorption) for Septic Shock in the ICU Unknown status NCT01639664 Phase 4
5 A Randomized Controlled Multi-Center Trial of the Early Application of CRRT in Patients With Severe Sepsis or Septic Shock Unknown status NCT00837057 Phase 4
6 Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the TerliNor Study Unknown status NCT03336814 Phase 4 Terlipressin
7 Potential Differences Between Levosimendan and Milrinone on Myocardial and Hemodynamic Variables in Patients With Septic Cardiomyopathy. Effects of Norepinephrine on Right Ventricular Function in Patient With Septic Shock. Unknown status NCT02640846 Phase 4 Norepinephrine;Milrinone;Levosimendan
8 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
9 Microcirculation Guided Therapy Versus "Standard Treatment" of Severe Sepsis Unknown status NCT00484133 Phase 4 Dopamine;dobutamine;enoximone;nitroglycerine;noradrenaline
10 Methylene Blue and Ozone in Early Sepsis , a Randomized Double Blind Trial Unknown status NCT02910765 Phase 4 methylene blue;ozone
11 Pharmacokinetics Variability of Ceftriaxone in Septic ICU Patients Unknown status NCT00449800 Phase 4 ceftriaxone
12 Importance of the Infusion Rate for the Plasma Expanding Effect of 5% Albumin in the Septic Patient Unknown status NCT03153306 Phase 4 albumin
13 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
14 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
15 Peripheral Perfusion Targeted Fluid Management in Critically Ill Patients: a Pilot Study Unknown status NCT01397474 Phase 4
16 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
17 Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study: a Multicenter, Prospective, Randomized Trial Comparing the State-of-the-Art Therapeutic Strategy Versus Early Surgery Strategy in Infective Endocarditis Unknown status NCT00624091 Phase 4
18 Continuous Administration of Norepinephrine Assisted by Fuzzy Logic Assisted Control in Septic Shock Patients Completed NCT00763906 Phase 4
19 An Evaluation of Vasopressor Requirement, Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa (Activated) as Part of Physician-Directed Therapy in Patients With Septic Shock Completed NCT00279214 Phase 4 drotrecogin alfa (activated)
20 The Effect of Fluids and Norepinephrine for Mean Arterial Pressure Titration to Patients' Usual Levels on the Microcirculation of Initial Resuscitated Hypertensive Septic Shock Patients. Completed NCT02085291 Phase 4 Norepinephrine;Crystalloid
21 Dexmedetomidine Improve Microcirculatory Alterations in Initial Resuscitated Septic Shock Patients Completed NCT02270281 Phase 4 Dexmedetomidine 0.7 Mcg/kg/h
22 Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis Completed NCT02805049 Phase 4 Echinocandins
23 Multicenter, Prospective, Randomized, Controlled Open Study Albumin 20% Versus Saline Completed NCT00327704 Phase 4 albumin;saline
24 Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C Completed NCT02885168 Phase 4 Recombinant Activated Protein C;Phenylephrine
25 Population Pharmacokinetics and Pharmacodynamics Study of Piperacillin/Tazobactam During Early Phase in Critically Ill Patients With Severe Sepsis Completed NCT02730624 Phase 4 Piperacillin-tazobactam
26 Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue in Sepsis: A Randomized Controlled Trial Completed NCT03120637 Phase 4 Methylene Blue
27 Hemodynamic Assessment With Transpulmonary Thermodilution and Transesophageal Echocardiography in Patients With Early Septic Shock Completed NCT01188993 Phase 4
28 A Randomised Blinded Placebo Controlled Trial of Hydrocortisone in Critically Ill Patients With Septic Shock Completed NCT01448109 Phase 4 Hydrocortisone;Sterile air filled vial
29 Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension Completed NCT02519699 Phase 4 norepinephrine
30 Basel Study for Evaluation of Starch (130;0.4) Infusion in Septic Patients: BaSES (130;0.4) Trial Completed NCT00273728 Phase 4 hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline
31 Hyperglycemia and Effects of Daily 100 Milligrams Versus 200 Milligrams of Hydrocortisone Therapy in Patients With Septic Shock: A Double-Blind Randomized Controlled Trial Completed NCT02266264 Phase 4 Hydrocortisone
32 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
33 Double Blinded, Randomized Trial, Comparing Intravenous Bolus of 50 mg of Hydrocortisone Every 6 Hours for 7 Days With a Continuous Infusion of 300 mg Per Day of Hydrocortisone 300-mg Group During 5 Days in the Treatment of Septic Shock. Completed NCT02768740 Phase 4 Hydrocortisone hemisuccinate
34 Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis Completed NCT01310790 Phase 4
35 Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units Completed NCT02213796 Phase 4 Meropenem
36 Dispositivo Adsorbente Con Polymyxina B Immobilizzata Nello Shock Settico - Studio Clinico Randomizzato e Prospettico, Multicentrico Completed NCT00629382 Phase 4
37 Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (CLASSIC) - a Randomised Clinical Trial Completed NCT02079402 Phase 4 Isotonic crystalloids
38 Investigating Nutritional Therapy With EPA, GLA and Antioxidants Role in Sepsis Treatment-INTERSEPT STUDY Completed NCT00329680 Phase 4
39 Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Amikacin in Patients With Severe Sepsis or Septic Shock Admitted at the Emergency Department(ED) Completed NCT02365272 Phase 4 Amikacin
40 Low-dose Hydrocortisone in the Treatment of the Shock of Burned Patients Completed NCT00149123 Phase 4 hydrocortisone 200 mg/day
41 The Effects of Different Vasopressors on the Innate Immune Response During Experimental Human Endotoxemia, a Pilot Proof-of-principle Study Completed NCT02675868 Phase 4 Norepinephrine;Phenylephrine;Vasopressins;Placebo
42 Adrenal Cortical Function and Vitamin A Deficiency in Sepsis, Severe Sepsis and Septic Shock: Prospective Randomized, Double Blind Placebo Controlled Clinical Trials Completed NCT03152474 Phase 4 Solumedrol 20mg;Vitamin A 100,000 IU
43 The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation Completed NCT01099566 Phase 4 Prasugrel;Placebo
44 The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia. Completed NCT01091571 Phase 4 Dipyridamole;Placebo
45 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4 vitamin and mineral supplement;Escherichia coli Endotoxin (LPS);100% O2;nitroglycerin
46 Efficacy and Toxicity of Aerosolised Colistin in Ventilator Associated Pneumonia: A Prospective, Randomized Trial Completed NCT02683603 Phase 4 AS colistin and "imipenem";IV colistin " and "imipenem" .;AS colimycin (colistin);IV colimycin (colistin);AS colistin and imipenem;IV colistin and imipenem
47 Randomized Directed Immuno Nutrition by L-arginine for Critically Ill Patients Completed NCT01038622 Phase 4 L-arginine;placebo
48 The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1 Completed NCT02384200 Phase 4 nitrofurantoin monohydrate/macrocrystalline capsules;ampicillin;gentamicin;vancomycin;ceftriaxone
49 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
50 Safety and Efficacy of Single Daily Dose of Ceftriaxone and Metronidazole for Treatment of Complicated Appendicitis in Children Completed NCT01678365 Phase 4 ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole

Search NIH Clinical Center for Toxic Shock Syndrome

Cochrane evidence based reviews: shock, septic

Genetic Tests for Toxic Shock Syndrome

Anatomical Context for Toxic Shock Syndrome

MalaCards organs/tissues related to Toxic Shock Syndrome:

40
Liver, Kidney, Lung, Heart, Neutrophil, T Cells, Endothelial

Publications for Toxic Shock Syndrome

Articles related to Toxic Shock Syndrome:

(show top 50) (show all 24824)
# Title Authors PMID Year
1
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. 54 61 6
10450718 1999
2
Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. 6
16418737 2006
3
An association between asthma and TNF-308G/A polymorphism: meta-analysis. 6
16865291 2006
4
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 6
14681301 2004
5
Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. 6
14718719 2004
6
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. 6
12746914 2003
7
Association between G-308A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. 6
12485196 2002
8
Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. 6
11826025 2002
9
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. 6
11896460 2002
10
Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. 6
11506397 2001
11
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 6
11261930 2001
12
Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. 6
9818939 1998
13
Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. 6
8056188 1994
14
Why not treat human cancer with interleukin-1 blockade? 54 61
20422276 2010
15
Spectrum of sepsis, mediators, source control and management of bundles. 54 61
20515762 2010
16
Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. 54 61
20421309 2010
17
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. 54 61
20004006 2010
18
The septic shock-associated IL-10 -1082 A > G polymorphism mediates allele-specific transcription via poly(ADP-Ribose) polymerase 1 in macrophages engulfing apoptotic cells. 54 61
20181890 2010
19
Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. 54 61
20119647 2010
20
Sepsis, leukocytes, and nitric oxide (NO): an intricate affair. 54 61
19789465 2010
21
Activated protein C and hospital mortality in septic shock: a propensity-matched analysis. 54 61
20154607 2010
22
C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. 54 61
19717486 2010
23
The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients. 54 61
20051843 2010
24
Augmentation of platelet and endothelial cell eNOS activity decreases sepsis-related neutrophil-endothelial cell interactions. 54 61
19536045 2010
25
The importance of determining procalcitonin and C reactive protein in different stages of sepsis. 54 61
20192933 2010
26
Immunogenicity of toxins during Staphylococcus aureus infection. 54 61
19947854 2010
27
Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. 54 61
20472994 2010
28
Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock. 54 61
20181046 2010
29
Toll-like receptor 4 modulation as a strategy to treat sepsis. 54 61
20396414 2010
30
[Gene polymorphisms of Toll-like receptors in Chinese Han children with sepsis in Wenzhou]. 54 61
20441696 2010
31
A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. 54 61
20165718 2010
32
beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. 54 61
19850944 2010
33
Early suspension of activated protein C treatment in septic patients after shock reversal. 54 61
19474736 2009
34
Serum macrophage migration inhibitory factor reflects adrenal function in the hypothalamo-pituitary-adrenal axis of septic patients: an observational study. 54 61
20021698 2009
35
Relation of heart rate variability to serum levels of C-reactive protein, interleukin 6, and 10 in patients with sepsis and septic shock. 54 61
19327330 2009
36
Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. 54 61
19450686 2009
37
Sick adrenal or sick euadrenal? 54 61
20001882 2009
38
Evidence lost to treatment of critically-ill patients? 54 61
19940825 2009
39
Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. 54 61
19760208 2009
40
Angiopoietin balance in septic shock patients treated by direct hemoperfusion with polymyxin b-immobilized fiber. 54 61
19954476 2009
41
C-reactive protein is not a useful indicator for infection in surgical intensive care units. 54 61
20512289 2009
42
Procalcitonin levels as an early marker in patients with multiple trauma under intensive care. 54 61
20146868 2009
43
Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock. 54 61
19793001 2009
44
The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. 54 61
19652948 2009
45
Urgent care in gynaecology: resuscitation and management of sepsis and acute blood loss. 54 61
19596611 2009
46
Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. 54 61
19740375 2009
47
Circulating angiopoietin-2 levels in the course of septic shock: relation with fluid balance, pulmonary dysfunction and mortality. 54 61
19551369 2009
48
Hemodynamic resuscitation in septic shock: cardiovascular support and adjunctive therapy. 54 61
19698279 2009
49
Soluble TNFR II/IgG1 Fc fusion protein treatment in the LPS-mediated septic shock of rats. 54 61
18848768 2009
50
Combined use of extracorporeal membrane oxygenation and activated protein C for severe acute respiratory distress syndrome and septic shock. 54 61
19577093 2009

Variations for Toxic Shock Syndrome

ClinVar genetic disease variations for Toxic Shock Syndrome:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TNF TNF, -308G-ASNV risk factor 12388

Expression for Toxic Shock Syndrome

Search GEO for disease gene expression data for Toxic Shock Syndrome.

Pathways for Toxic Shock Syndrome

Pathways related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.14 TREM1 TNF TLR4 TLR2 LTA LBP
2
Show member pathways
13.82 TNF TLR4 LTA IL6 IL4 IL2
3